李浩



[摘要] 目的 探討哮喘-慢阻肺重叠综合征(ACOS)患者联用吸入激素与噻托溴铵的临床效果。方法 该研究方便选取2015年12月—2018年6月期间就诊的66例ACOS患者,以随机数字表法将其分入研究组、对照组两组,两组患者例数相同。对照组仅用吸入激素进行治疗,研究组加用噻托溴铵。对比两组的发作周期、治疗后的肺功能指标、并发症发生率、临床疗效、用药不良反应等指标。结果 研究组具有93.94%的治疗总有效率,比对照组的75.76%高,差异有统计学意义(χ2=4.243,P=0.039 <0.05)。研究组治疗后的发作周期为(9.43±2.46)d,比对照组的(5.23±0.45)d长,差异有统计学意义(t=9.648,P=0.000 <0.05)。研究组并发症发生率为6.06 %,低于对照组的30.30%,差异有统计学意义(χ2=6.519,P=0.011 < 0.05)。两组用药不良反应率相近,差异无统计学意义(χ2=1.015,P=0.314 > 0.05)。此外,研究组治疗后的肺功能指标吸气分数、1秒用力呼气量分别为(49.22±4.43)%和(1.98±0.65)L,均比对照组的(39.19±3.37)%和(1.19±0.35)L高,而残总比为(28.08±2.66)%,则比对照组的(39.56±3.34)%低,差异有统计学意义(t=10.352、6.147、15.485,P<0.05)。结论 为ACOS患者联用吸入激素、噻托溴铵可比单用吸入激素更有效地改善肺功能、延后发作,同时不必担心严重并发症发生。
[关键词] 哮喘-慢阻肺重叠综合征;噻托溴铵;吸入激素;联合;治疗效果
[中图分类号] R473 [文献标识码] A [文章编号] 1674-0742(2020)06(a)-0010-03
Analysis of the Effect of Inhaled Hormone Combined with Tiotropium Bromide on Asthma-coronary Obstruction Syndrome
LI Hao
Department of Respiratory and Critical Care Medicine,Zhangzhou Hospital,Fujian Medical University,Zhangzhou,Fujian Province,363000 China
[Abstract] Objective To observe the clinical effect of combined inhaled hormone and tiotropium bromide in patients with asthma-coronary obstruction syndrome (ACOS). Methods In this study,66 ACOS patients who were convenient treated from December 2015 to June 2018 were randomly divided into study group and control group. The number of patients in the two groups was the same. The control group was treated with inhaled hormones only,and the study group was treated with tiotropium bromide. The two groups were compared for their seizure cycle,pulmonary function indexes,complication rate,clinical efficacy,and adverse drug reactions. Results The total effective rate of treatment in the study group was 93.94%,which was higher than 75.76% in the control group. The difference was statistically significant (χ2=4.243,P=0.039 <0.05). The attack period in the study group after treatment was (9.43±2.46) d ,which was longer than the control group (5.23±0.45) d ,and the difference was statistically significant (t=9.648,P=0.000 <0.05). The incidence of complications in the study group was 6.06%,which was lower than the control group's 30.30%,and the difference was statistically significant (χ2=6.519,P=0.011 <0.05). The adverse drug reaction rates between the two groups were similar,and the difference was not statistically significant (χ2=1.015,P=0.314> 0.05). In addition,the lung function index inspiratory fraction and forced expiratory volume in 1 second of the study group were (49.22±4.43)% and (1.98±0.65) L,respectively,which were both (39.19±3.37)% and (1.19±0.35) L,and the total residual ratio was (28.08±2.66)%,lower than (39.56±3.34)% of the control group,and the difference is statistically significant (t=10.352,6.147,15.485,P<0.05 ). Conclusion The combined use of inhaled hormone and tiotropium in patients with ACOS can improve lung function and delay seizures more than inhaled hormone alone,without worrying about serious complications.
[Key words] Asthma-COPD overlap syndrome; Tiotropium bromide; Inhaled hormones; Combined;Treatment effect
支气管哮喘是呼吸科常见病,慢性阻塞性肺疾病也是如此,二者均属于慢性炎症,患者均有气流受限、呼吸困难、气道阻塞等症状,由于二者在发病原因、诱发因素以及临床特征等多个方面都有所重叠,故合并患有2种疾病会被称为“哮喘-慢阻肺重叠综合征(ACOS)”,若不及时治疗将会使病情加重、使肺功能受损,进而危及患者生命健康[1]。但是,二者也有所不同,例如慢阻肺的支气管阻塞是进行性的,部分可逆,而支气管哮喘则是完全可逆,因此单一的药物大多仅能有效治疗二者中的一种,而无法对ACOS产生理想效果,临床因此而需要进行多药治疗,以取得较好的治疗效果。该文方便选取2015年12月—2018年6月期间就诊的66例ACOS患者,试观察ACOS患者联用吸入激素与噻托溴铵的临床效果。……